| 生物活性 | |||
|---|---|---|---|
| 描述 | MY-5445 acts as a specific antagonist of cyclic GMP phosphodiesterase, particularly PDE5, exhibiting a Ki value of 1.3 μM. It effectively prevents human platelet aggregation and modulates the ATP-binding cassette transporter ABCG2 selectively, leading to an anti-proliferative effect[1][2]. Additionally, MY-5445 curbs human platelet aggregation by elevating cyclic GMP levels, serving as a valuable tool for investigating the role of cyclic GMP in this process[1]. MY-5445 selectively counteracts the ABCG2-mediated multidrug resistance in cells with high levels of ABCG2. It enhances the effectiveness of an ABCG2 substrate drug against ABCG2-overexpressing cancer cells resistant to multiple drugs, likely through altering ABCG2's function and/or expression. Additionally, a 48-hour treatment with MY-5445 at a concentration of 3 μM significantly augments apoptosis in S1-M1-80 cells induced by topotecan[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
| 1 mM 5 mM 10 mM | 3.01mL 0.60mL 0.30mL | 15.07mL 3.01mL 1.51mL | 30.14mL 6.03mL 3.01mL | 
| 参考文献 | 
|---|